Several observations have suggested that inactivation of RB in the genome or in the phenotype can lead to abnormal expression of p16INK4a or cyclin D1, and promote cell cycle G1-S transition, resulting in sensitivity to loss of inhibition by ERα in cancer cells [39,40]. Here, RB1 is linked to cancer.